Perceptive Advisors’s Contineum Therapeutics CTNM Stock Holding History

Perceptive Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.4M	Sell	1,255,592 -209,000	-14%	-$2.8M	0.32%	58
2025 Q4	$16.7M	Buy	1,464,592 +750,000	+105%	+$8.56M	0.3%	67
2025 Q3	$8.4M	Buy	714,592 +15,106	+2%	+$122K	0.24%	62
2025 Q2	$2.78M	Sell	699,486 -741,763	-51%	-$3.22M	0.1%	70
2025 Q1	$10.1M	Hold	1,441,249	–	–	0.36%	54
2024 Q4	$21.1M	Sell	1,441,249 -75,419	-5%	-$1.19M	0.58%	40
2024 Q3	$29M	Sell	1,516,668 -50,000	-3%	-$959K	0.61%	40
2024 Q2	$27.6M	Buy	+1,566,668	New	+$25.2M	0.66%	44

Other funds holding CTNM

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors's CTNM Position: Q1 2026 in Review

Perceptive Advisors reduced its Contineum Therapeutics (CTNM) stake by 14% in Q1 2026, selling an estimated $2.8M and leaving 1,255,592 shares worth $16.4M. The position accounts for 0.32% of the portfolio, ranked #58.

Perceptive Advisors first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $29M in Q3 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

Perceptive Advisors held 1,255,592 shares of Contineum Therapeutics worth $16.4M as of Q1 2026.
Perceptive Advisors sold 209,000 Contineum Therapeutics shares in Q1 2026, an estimated $2.8M.
Contineum Therapeutics made up 0.32% of Perceptive Advisors's portfolio in Q1 2026, its #58 holding.
Perceptive Advisors first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
Perceptive Advisors's Contineum Therapeutics position peaked at $29M in Q3 2024.
90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.